This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by del Monte, F. Articles by Inesi, G. Search for Related Content PubMed PubMed Citation Articles by del Monte, F. Articles by Inesi, G.

(Circulation Research. 2001;88:e66.)
© 2001 American Heart Association, Inc.

Letter to the Editor

Overwhelming Evidence of the Beneficial Effects of SERCA Gene Transfer in Heart Failure

Federica del Monte, Roger J. Hajjar

Harvard Medical School, Massachusetts General Hospital, Cardiovascular Research Center, Charlestown, Mass, hajjar@cvrc.mgh.harvard.edu

Sian E. Harding

Imperial College, London, UK

To the Editor:

We read with great interest the work by O’Donnell et al¹ on the possible toxic effect of the sarcoplasmic reticulum Ca²⁺ ATPase pump in neonatal cardiac myocytes. Because gene transfer of SERCA2a is being currently considered as a modality for the treatment of heart failure,² the work by O’Donnell et al has the potential of raising concern about such a strategy. However, a number of limitations in this study preclude any definitive conclusions regarding the toxicity of overexpressing SERCA. The authors demonstrated the expression of the noncardiac isoform SERCA1 in embryonic and neonatal cardiac myocytes in their studies. These cardiomyocytes have a poorly developed sarcoplasmic reticulum and do not represent functionally the adult heart. In addition, the expression of the SERCA1 isoform may result in abnormal intracellular trafficking, which results in irregular calcium signaling. Although the authors state that cytotoxic effects observed with SERCA1 overexpression are "slightly" higher than with the empty or reporter viruses, no statistical significance is shown. The apoptosis index, which is unusually high in this study compared with other published studies,³ is not reportedly different between SERCA1 overexpression or GFP overexpression. The conclusions drawn in this study are in direct contrast to those validated by numerous experimental results showing that overexpression of the cardiac isoform, SERCA2a, improves contractility both in vivo and in vitro without detrimental effects.^{4 5 6} Most importantly, a recent study by Davia et al⁷ showed that overexpression of SERCA2a in adult rabbit cardiac myocytes has protective effects in contrast to ß-agonism . . . [Full Text of this Article]

Giuseppe Inesi

Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, Md, ginesi@umaryland.edu